Global Oligonucleotide Drug Delivery Market Research Report 2025

Publication ID:

PB505257925

Publication Date:

May 30, 2025

Pages:

100

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global market for Oligonucleotide Drug Delivery was valued at US$ 12900 million in the year 2024 and is projected to reach a revised size of US$ 16590 million by 2031, growing at a CAGR of 3.7% during the forecast period.
Oligonucleotides can be used to modulate gene expression via a range of processes including RNAi, target degradation by RNase H-mediated cleavage, splicing modulation, non-coding RNA inhibition, gene activation and programmed gene editing.
The Oligonucleotide Drug Delivery Market is driven by the rapid advancement in oligonucleotide-based therapies, including antisense, siRNA, and aptamer-based drugs, which hold immense potential for treating various genetic and rare diseases. These therapies rely on oligonucleotides to modulate gene expression, inhibit specific targets, or diagnose genetic disorders. As the understanding of genetic mechanisms and precision medicine continues to evolve, the demand for efficient and targeted delivery systems for oligonucleotide drugs grows. Innovations in drug delivery technologies, such as lipid nanoparticles and conjugates, as well as the expansion of oligonucleotide drug pipelines, further contribute to market expansion. However, a significant challenge for this market is the need to address the complexity of drug delivery, including overcoming biological barriers, minimizing off-target effects, and ensuring long-term safety and efficacy. Overcoming delivery hurdles, optimizing pharmacokinetics, and navigating regulatory pathways are ongoing challenges. Additionally, the market faces competition from traditional drug therapies, and the need for continuous research and development to enhance the delivery efficiency and patient acceptance of oligonucleotide drugs. Striking a balance between providing efficient and precise oligonucleotide drug delivery solutions while addressing safety and regulatory considerations is crucial for the continued growth of the Oligonucleotide Drug Delivery Market.
This report aims to provide a comprehensive presentation of the global market for Oligonucleotide Drug Delivery, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oligonucleotide Drug Delivery.
The Oligonucleotide Drug Delivery market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Oligonucleotide Drug Delivery market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oligonucleotide Drug Delivery companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Sarepta Therapeutics
Ionis Pharmaceuticals
Alnylam
Biogen
Nippon Shinyaku
Sobi
Novartis
BioNTech
Pfizer
Moderna Therapeutics
Jazz Pharmaceuticals
CureVac
Regulus Therapeutics
ProQR
Secarna
MiNA Therapeutics
Sylentis
Arrowhead
Silence Therapeutics
Dicerna
Segment by Type
Antisense Oligonucleotides (ASO)
siRNA
mRNA
Segment by Application
Neuromuscular Diseases
hATTR
COVID-19
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Oligonucleotide Drug Delivery company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oligonucleotide Drug Delivery Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Antisense Oligonucleotides (ASO)
1.2.3 siRNA
1.2.4 mRNA
1.3 Market by Application
1.3.1 Global Oligonucleotide Drug Delivery Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Neuromuscular Diseases
1.3.3 hATTR
1.3.4 COVID-19
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Oligonucleotide Drug Delivery Market Perspective (2020-2031)
2.2 Global Oligonucleotide Drug Delivery Growth Trends by Region
2.2.1 Global Oligonucleotide Drug Delivery Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Oligonucleotide Drug Delivery Historic Market Size by Region (2020-2025)
2.2.3 Oligonucleotide Drug Delivery Forecasted Market Size by Region (2026-2031)
2.3 Oligonucleotide Drug Delivery Market Dynamics
2.3.1 Oligonucleotide Drug Delivery Industry Trends
2.3.2 Oligonucleotide Drug Delivery Market Drivers
2.3.3 Oligonucleotide Drug Delivery Market Challenges
2.3.4 Oligonucleotide Drug Delivery Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Oligonucleotide Drug Delivery Players by Revenue
3.1.1 Global Top Oligonucleotide Drug Delivery Players by Revenue (2020-2025)
3.1.2 Global Oligonucleotide Drug Delivery Revenue Market Share by Players (2020-2025)
3.2 Global Oligonucleotide Drug Delivery Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Oligonucleotide Drug Delivery Revenue
3.4 Global Oligonucleotide Drug Delivery Market Concentration Ratio
3.4.1 Global Oligonucleotide Drug Delivery Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oligonucleotide Drug Delivery Revenue in 2024
3.5 Global Key Players of Oligonucleotide Drug Delivery Head office and Area Served
3.6 Global Key Players of Oligonucleotide Drug Delivery, Product and Application
3.7 Global Key Players of Oligonucleotide Drug Delivery, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Oligonucleotide Drug Delivery Breakdown Data by Type
4.1 Global Oligonucleotide Drug Delivery Historic Market Size by Type (2020-2025)
4.2 Global Oligonucleotide Drug Delivery Forecasted Market Size by Type (2026-2031)
5 Oligonucleotide Drug Delivery Breakdown Data by Application
5.1 Global Oligonucleotide Drug Delivery Historic Market Size by Application (2020-2025)
5.2 Global Oligonucleotide Drug Delivery Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Oligonucleotide Drug Delivery Market Size (2020-2031)
6.2 North America Oligonucleotide Drug Delivery Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Oligonucleotide Drug Delivery Market Size by Country (2020-2025)
6.4 North America Oligonucleotide Drug Delivery Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Oligonucleotide Drug Delivery Market Size (2020-2031)
7.2 Europe Oligonucleotide Drug Delivery Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Oligonucleotide Drug Delivery Market Size by Country (2020-2025)
7.4 Europe Oligonucleotide Drug Delivery Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Oligonucleotide Drug Delivery Market Size (2020-2031)
8.2 Asia-Pacific Oligonucleotide Drug Delivery Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Oligonucleotide Drug Delivery Market Size by Region (2020-2025)
8.4 Asia-Pacific Oligonucleotide Drug Delivery Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Oligonucleotide Drug Delivery Market Size (2020-2031)
9.2 Latin America Oligonucleotide Drug Delivery Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Oligonucleotide Drug Delivery Market Size by Country (2020-2025)
9.4 Latin America Oligonucleotide Drug Delivery Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Oligonucleotide Drug Delivery Market Size (2020-2031)
10.2 Middle East & Africa Oligonucleotide Drug Delivery Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Oligonucleotide Drug Delivery Market Size by Country (2020-2025)
10.4 Middle East & Africa Oligonucleotide Drug Delivery Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Sarepta Therapeutics
11.1.1 Sarepta Therapeutics Company Details
11.1.2 Sarepta Therapeutics Business Overview
11.1.3 Sarepta Therapeutics Oligonucleotide Drug Delivery Introduction
11.1.4 Sarepta Therapeutics Revenue in Oligonucleotide Drug Delivery Business (2020-2025)
11.1.5 Sarepta Therapeutics Recent Development
11.2 Ionis Pharmaceuticals
11.2.1 Ionis Pharmaceuticals Company Details
11.2.2 Ionis Pharmaceuticals Business Overview
11.2.3 Ionis Pharmaceuticals Oligonucleotide Drug Delivery Introduction
11.2.4 Ionis Pharmaceuticals Revenue in Oligonucleotide Drug Delivery Business (2020-2025)
11.2.5 Ionis Pharmaceuticals Recent Development
11.3 Alnylam
11.3.1 Alnylam Company Details
11.3.2 Alnylam Business Overview
11.3.3 Alnylam Oligonucleotide Drug Delivery Introduction
11.3.4 Alnylam Revenue in Oligonucleotide Drug Delivery Business (2020-2025)
11.3.5 Alnylam Recent Development
11.4 Biogen
11.4.1 Biogen Company Details
11.4.2 Biogen Business Overview
11.4.3 Biogen Oligonucleotide Drug Delivery Introduction
11.4.4 Biogen Revenue in Oligonucleotide Drug Delivery Business (2020-2025)
11.4.5 Biogen Recent Development
11.5 Nippon Shinyaku
11.5.1 Nippon Shinyaku Company Details
11.5.2 Nippon Shinyaku Business Overview
11.5.3 Nippon Shinyaku Oligonucleotide Drug Delivery Introduction
11.5.4 Nippon Shinyaku Revenue in Oligonucleotide Drug Delivery Business (2020-2025)
11.5.5 Nippon Shinyaku Recent Development
11.6 Sobi
11.6.1 Sobi Company Details
11.6.2 Sobi Business Overview
11.6.3 Sobi Oligonucleotide Drug Delivery Introduction
11.6.4 Sobi Revenue in Oligonucleotide Drug Delivery Business (2020-2025)
11.6.5 Sobi Recent Development
11.7 Novartis
11.7.1 Novartis Company Details
11.7.2 Novartis Business Overview
11.7.3 Novartis Oligonucleotide Drug Delivery Introduction
11.7.4 Novartis Revenue in Oligonucleotide Drug Delivery Business (2020-2025)
11.7.5 Novartis Recent Development
11.8 BioNTech
11.8.1 BioNTech Company Details
11.8.2 BioNTech Business Overview
11.8.3 BioNTech Oligonucleotide Drug Delivery Introduction
11.8.4 BioNTech Revenue in Oligonucleotide Drug Delivery Business (2020-2025)
11.8.5 BioNTech Recent Development
11.9 Pfizer
11.9.1 Pfizer Company Details
11.9.2 Pfizer Business Overview
11.9.3 Pfizer Oligonucleotide Drug Delivery Introduction
11.9.4 Pfizer Revenue in Oligonucleotide Drug Delivery Business (2020-2025)
11.9.5 Pfizer Recent Development
11.10 Moderna Therapeutics
11.10.1 Moderna Therapeutics Company Details
11.10.2 Moderna Therapeutics Business Overview
11.10.3 Moderna Therapeutics Oligonucleotide Drug Delivery Introduction
11.10.4 Moderna Therapeutics Revenue in Oligonucleotide Drug Delivery Business (2020-2025)
11.10.5 Moderna Therapeutics Recent Development
11.11 Jazz Pharmaceuticals
11.11.1 Jazz Pharmaceuticals Company Details
11.11.2 Jazz Pharmaceuticals Business Overview
11.11.3 Jazz Pharmaceuticals Oligonucleotide Drug Delivery Introduction
11.11.4 Jazz Pharmaceuticals Revenue in Oligonucleotide Drug Delivery Business (2020-2025)
11.11.5 Jazz Pharmaceuticals Recent Development
11.12 CureVac
11.12.1 CureVac Company Details
11.12.2 CureVac Business Overview
11.12.3 CureVac Oligonucleotide Drug Delivery Introduction
11.12.4 CureVac Revenue in Oligonucleotide Drug Delivery Business (2020-2025)
11.12.5 CureVac Recent Development
11.13 Regulus Therapeutics
11.13.1 Regulus Therapeutics Company Details
11.13.2 Regulus Therapeutics Business Overview
11.13.3 Regulus Therapeutics Oligonucleotide Drug Delivery Introduction
11.13.4 Regulus Therapeutics Revenue in Oligonucleotide Drug Delivery Business (2020-2025)
11.13.5 Regulus Therapeutics Recent Development
11.14 ProQR
11.14.1 ProQR Company Details
11.14.2 ProQR Business Overview
11.14.3 ProQR Oligonucleotide Drug Delivery Introduction
11.14.4 ProQR Revenue in Oligonucleotide Drug Delivery Business (2020-2025)
11.14.5 ProQR Recent Development
11.15 Secarna
11.15.1 Secarna Company Details
11.15.2 Secarna Business Overview
11.15.3 Secarna Oligonucleotide Drug Delivery Introduction
11.15.4 Secarna Revenue in Oligonucleotide Drug Delivery Business (2020-2025)
11.15.5 Secarna Recent Development
11.16 MiNA Therapeutics
11.16.1 MiNA Therapeutics Company Details
11.16.2 MiNA Therapeutics Business Overview
11.16.3 MiNA Therapeutics Oligonucleotide Drug Delivery Introduction
11.16.4 MiNA Therapeutics Revenue in Oligonucleotide Drug Delivery Business (2020-2025)
11.16.5 MiNA Therapeutics Recent Development
11.17 Sylentis
11.17.1 Sylentis Company Details
11.17.2 Sylentis Business Overview
11.17.3 Sylentis Oligonucleotide Drug Delivery Introduction
11.17.4 Sylentis Revenue in Oligonucleotide Drug Delivery Business (2020-2025)
11.17.5 Sylentis Recent Development
11.18 Arrowhead
11.18.1 Arrowhead Company Details
11.18.2 Arrowhead Business Overview
11.18.3 Arrowhead Oligonucleotide Drug Delivery Introduction
11.18.4 Arrowhead Revenue in Oligonucleotide Drug Delivery Business (2020-2025)
11.18.5 Arrowhead Recent Development
11.19 Silence Therapeutics
11.19.1 Silence Therapeutics Company Details
11.19.2 Silence Therapeutics Business Overview
11.19.3 Silence Therapeutics Oligonucleotide Drug Delivery Introduction
11.19.4 Silence Therapeutics Revenue in Oligonucleotide Drug Delivery Business (2020-2025)
11.19.5 Silence Therapeutics Recent Development
11.20 Dicerna
11.20.1 Dicerna Company Details
11.20.2 Dicerna Business Overview
11.20.3 Dicerna Oligonucleotide Drug Delivery Introduction
11.20.4 Dicerna Revenue in Oligonucleotide Drug Delivery Business (2020-2025)
11.20.5 Dicerna Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

Companies Mentioned:

Sarepta Therapeutics
Ionis Pharmaceuticals
Alnylam
Biogen
Nippon Shinyaku
Sobi
Novartis
BioNTech
Pfizer
Moderna Therapeutics
Jazz Pharmaceuticals
CureVac
Regulus Therapeutics
ProQR
Secarna
MiNA Therapeutics
Sylentis
Arrowhead
Silence Therapeutics
Dicerna

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂